nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Abnormal vision—Epirubicin—ovarian cancer	0.00302	0.00302	CcSEcCtD
Apraclonidine—Pharyngitis—Paclitaxel—ovarian cancer	0.00302	0.00302	CcSEcCtD
Apraclonidine—Oedema peripheral—Paclitaxel—ovarian cancer	0.00299	0.00299	CcSEcCtD
Apraclonidine—Pruritus—Chlorambucil—ovarian cancer	0.00298	0.00298	CcSEcCtD
Apraclonidine—Abdominal pain—Topotecan—ovarian cancer	0.00297	0.00297	CcSEcCtD
Apraclonidine—Dry eye—Doxorubicin—ovarian cancer	0.00296	0.00296	CcSEcCtD
Apraclonidine—Visual impairment—Paclitaxel—ovarian cancer	0.00293	0.00293	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.00292	0.00292	CcSEcCtD
Apraclonidine—Diarrhoea—Chlorambucil—ovarian cancer	0.00288	0.00288	CcSEcCtD
Apraclonidine—Paraesthesia—Vinorelbine—ovarian cancer	0.00288	0.00288	CcSEcCtD
Apraclonidine—Infestation NOS—Docetaxel—ovarian cancer	0.00287	0.00287	CcSEcCtD
Apraclonidine—Infestation—Docetaxel—ovarian cancer	0.00287	0.00287	CcSEcCtD
Apraclonidine—Dyspnoea—Vinorelbine—ovarian cancer	0.00286	0.00286	CcSEcCtD
Apraclonidine—Eye disorder—Paclitaxel—ovarian cancer	0.00284	0.00284	CcSEcCtD
Apraclonidine—Abnormal vision—Doxorubicin—ovarian cancer	0.00279	0.00279	CcSEcCtD
Apraclonidine—Conjunctivitis—Docetaxel—ovarian cancer	0.00279	0.00279	CcSEcCtD
Apraclonidine—Eye pain—Epirubicin—ovarian cancer	0.00278	0.00278	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.00277	0.00277	CcSEcCtD
Apraclonidine—Fatigue—Vinorelbine—ovarian cancer	0.00277	0.00277	CcSEcCtD
Apraclonidine—Hypersensitivity—Topotecan—ovarian cancer	0.00276	0.00276	CcSEcCtD
Apraclonidine—Angiopathy—Paclitaxel—ovarian cancer	0.00276	0.00276	CcSEcCtD
Apraclonidine—Constipation—Vinorelbine—ovarian cancer	0.00274	0.00274	CcSEcCtD
Apraclonidine—Pain—Vinorelbine—ovarian cancer	0.00274	0.00274	CcSEcCtD
Apraclonidine—Mediastinal disorder—Paclitaxel—ovarian cancer	0.00274	0.00274	CcSEcCtD
Apraclonidine—Arrhythmia—Paclitaxel—ovarian cancer	0.00271	0.00271	CcSEcCtD
Apraclonidine—Hypersensitivity—Melphalan—ovarian cancer	0.00271	0.00271	CcSEcCtD
Apraclonidine—Asthenia—Topotecan—ovarian cancer	0.00269	0.00269	CcSEcCtD
Apraclonidine—Vomiting—Chlorambucil—ovarian cancer	0.00268	0.00268	CcSEcCtD
Apraclonidine—Mental disorder—Paclitaxel—ovarian cancer	0.00266	0.00266	CcSEcCtD
Apraclonidine—Pruritus—Topotecan—ovarian cancer	0.00265	0.00265	CcSEcCtD
Apraclonidine—Erythema—Paclitaxel—ovarian cancer	0.00265	0.00265	CcSEcCtD
Apraclonidine—Feeling abnormal—Vinorelbine—ovarian cancer	0.00264	0.00264	CcSEcCtD
Apraclonidine—Asthenia—Melphalan—ovarian cancer	0.00264	0.00264	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.00262	0.00262	CcSEcCtD
Apraclonidine—Pruritus—Melphalan—ovarian cancer	0.0026	0.0026	CcSEcCtD
Apraclonidine—Tension—Paclitaxel—ovarian cancer	0.0026	0.0026	CcSEcCtD
Apraclonidine—Dysgeusia—Paclitaxel—ovarian cancer	0.00259	0.00259	CcSEcCtD
Apraclonidine—Rhinitis—Docetaxel—ovarian cancer	0.00258	0.00258	CcSEcCtD
Apraclonidine—Haemorrhage—Docetaxel—ovarian cancer	0.00258	0.00258	CcSEcCtD
Apraclonidine—Eye pain—Doxorubicin—ovarian cancer	0.00257	0.00257	CcSEcCtD
Apraclonidine—Nervousness—Paclitaxel—ovarian cancer	0.00257	0.00257	CcSEcCtD
Apraclonidine—Diarrhoea—Topotecan—ovarian cancer	0.00257	0.00257	CcSEcCtD
Apraclonidine—Pharyngitis—Docetaxel—ovarian cancer	0.00256	0.00256	CcSEcCtD
Apraclonidine—Abdominal pain—Vinorelbine—ovarian cancer	0.00254	0.00254	CcSEcCtD
Apraclonidine—Oedema peripheral—Docetaxel—ovarian cancer	0.00254	0.00254	CcSEcCtD
Apraclonidine—Diarrhoea—Melphalan—ovarian cancer	0.00251	0.00251	CcSEcCtD
Apraclonidine—Nausea—Chlorambucil—ovarian cancer	0.0025	0.0025	CcSEcCtD
Apraclonidine—Vision blurred—Paclitaxel—ovarian cancer	0.00249	0.00249	CcSEcCtD
Apraclonidine—Visual impairment—Docetaxel—ovarian cancer	0.00248	0.00248	CcSEcCtD
Apraclonidine—Dizziness—Topotecan—ovarian cancer	0.00248	0.00248	CcSEcCtD
Apraclonidine—Ill-defined disorder—Paclitaxel—ovarian cancer	0.00245	0.00245	CcSEcCtD
Apraclonidine—Face oedema—Epirubicin—ovarian cancer	0.00242	0.00242	CcSEcCtD
Apraclonidine—Eye disorder—Docetaxel—ovarian cancer	0.00241	0.00241	CcSEcCtD
Apraclonidine—Vomiting—Topotecan—ovarian cancer	0.00239	0.00239	CcSEcCtD
Apraclonidine—Malaise—Paclitaxel—ovarian cancer	0.00239	0.00239	CcSEcCtD
Apraclonidine—Syncope—Paclitaxel—ovarian cancer	0.00237	0.00237	CcSEcCtD
Apraclonidine—Hypersensitivity—Vinorelbine—ovarian cancer	0.00236	0.00236	CcSEcCtD
Apraclonidine—Dermatitis—Topotecan—ovarian cancer	0.00236	0.00236	CcSEcCtD
Apraclonidine—Headache—Topotecan—ovarian cancer	0.00235	0.00235	CcSEcCtD
Apraclonidine—Palpitations—Paclitaxel—ovarian cancer	0.00234	0.00234	CcSEcCtD
Apraclonidine—Angiopathy—Docetaxel—ovarian cancer	0.00234	0.00234	CcSEcCtD
Apraclonidine—Vomiting—Melphalan—ovarian cancer	0.00234	0.00234	CcSEcCtD
Apraclonidine—Mediastinal disorder—Docetaxel—ovarian cancer	0.00232	0.00232	CcSEcCtD
Apraclonidine—Dermatitis—Melphalan—ovarian cancer	0.00231	0.00231	CcSEcCtD
Apraclonidine—Asthenia—Vinorelbine—ovarian cancer	0.0023	0.0023	CcSEcCtD
Apraclonidine—Arrhythmia—Docetaxel—ovarian cancer	0.0023	0.0023	CcSEcCtD
Apraclonidine—Pruritus—Vinorelbine—ovarian cancer	0.00227	0.00227	CcSEcCtD
Apraclonidine—Mental disorder—Docetaxel—ovarian cancer	0.00226	0.00226	CcSEcCtD
Apraclonidine—Myalgia—Paclitaxel—ovarian cancer	0.00225	0.00225	CcSEcCtD
Apraclonidine—Chest pain—Paclitaxel—ovarian cancer	0.00225	0.00225	CcSEcCtD
Apraclonidine—Nasopharyngitis—Epirubicin—ovarian cancer	0.00225	0.00225	CcSEcCtD
Apraclonidine—Face oedema—Doxorubicin—ovarian cancer	0.00224	0.00224	CcSEcCtD
Apraclonidine—Erythema—Docetaxel—ovarian cancer	0.00224	0.00224	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.00224	0.00224	CcSEcCtD
Apraclonidine—Nausea—Topotecan—ovarian cancer	0.00223	0.00223	CcSEcCtD
Apraclonidine—Discomfort—Paclitaxel—ovarian cancer	0.00223	0.00223	CcSEcCtD
Apraclonidine—Dry mouth—Paclitaxel—ovarian cancer	0.0022	0.0022	CcSEcCtD
Apraclonidine—Diarrhoea—Vinorelbine—ovarian cancer	0.0022	0.0022	CcSEcCtD
Apraclonidine—Dysgeusia—Docetaxel—ovarian cancer	0.0022	0.0022	CcSEcCtD
Apraclonidine—Nausea—Melphalan—ovarian cancer	0.00218	0.00218	CcSEcCtD
Apraclonidine—Asthma—Epirubicin—ovarian cancer	0.00217	0.00217	CcSEcCtD
Apraclonidine—Oedema—Paclitaxel—ovarian cancer	0.00216	0.00216	CcSEcCtD
Apraclonidine—Infection—Paclitaxel—ovarian cancer	0.00214	0.00214	CcSEcCtD
Apraclonidine—Dizziness—Vinorelbine—ovarian cancer	0.00212	0.00212	CcSEcCtD
Apraclonidine—Nervous system disorder—Paclitaxel—ovarian cancer	0.00212	0.00212	CcSEcCtD
Apraclonidine—Skin disorder—Paclitaxel—ovarian cancer	0.0021	0.0021	CcSEcCtD
Apraclonidine—Nasopharyngitis—Doxorubicin—ovarian cancer	0.00208	0.00208	CcSEcCtD
Apraclonidine—Vomiting—Vinorelbine—ovarian cancer	0.00204	0.00204	CcSEcCtD
Apraclonidine—Dermatitis—Vinorelbine—ovarian cancer	0.00202	0.00202	CcSEcCtD
Apraclonidine—Headache—Vinorelbine—ovarian cancer	0.00201	0.00201	CcSEcCtD
Apraclonidine—Syncope—Docetaxel—ovarian cancer	0.00201	0.00201	CcSEcCtD
Apraclonidine—Asthma—Doxorubicin—ovarian cancer	0.00201	0.00201	CcSEcCtD
Apraclonidine—Palpitations—Docetaxel—ovarian cancer	0.00198	0.00198	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.00197	0.00197	CcSEcCtD
Apraclonidine—Insomnia—Paclitaxel—ovarian cancer	0.00195	0.00195	CcSEcCtD
Apraclonidine—Paraesthesia—Paclitaxel—ovarian cancer	0.00194	0.00194	CcSEcCtD
Apraclonidine—Infestation NOS—Epirubicin—ovarian cancer	0.00194	0.00194	CcSEcCtD
Apraclonidine—Infestation—Epirubicin—ovarian cancer	0.00194	0.00194	CcSEcCtD
Apraclonidine—Dyspnoea—Paclitaxel—ovarian cancer	0.00192	0.00192	CcSEcCtD
Apraclonidine—Somnolence—Paclitaxel—ovarian cancer	0.00192	0.00192	CcSEcCtD
Apraclonidine—Chest pain—Docetaxel—ovarian cancer	0.00191	0.00191	CcSEcCtD
Apraclonidine—Myalgia—Docetaxel—ovarian cancer	0.00191	0.00191	CcSEcCtD
Apraclonidine—Nausea—Vinorelbine—ovarian cancer	0.00191	0.00191	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.0019	0.0019	CcSEcCtD
Apraclonidine—Conjunctivitis—Epirubicin—ovarian cancer	0.00188	0.00188	CcSEcCtD
Apraclonidine—Dry mouth—Docetaxel—ovarian cancer	0.00187	0.00187	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.00186	0.00186	CcSEcCtD
Apraclonidine—Fatigue—Paclitaxel—ovarian cancer	0.00186	0.00186	CcSEcCtD
Apraclonidine—Constipation—Paclitaxel—ovarian cancer	0.00185	0.00185	CcSEcCtD
Apraclonidine—Pain—Paclitaxel—ovarian cancer	0.00185	0.00185	CcSEcCtD
Apraclonidine—Oedema—Docetaxel—ovarian cancer	0.00183	0.00183	CcSEcCtD
Apraclonidine—Infection—Docetaxel—ovarian cancer	0.00182	0.00182	CcSEcCtD
Apraclonidine—Nervous system disorder—Docetaxel—ovarian cancer	0.00179	0.00179	CcSEcCtD
Apraclonidine—Infestation—Doxorubicin—ovarian cancer	0.00179	0.00179	CcSEcCtD
Apraclonidine—Infestation NOS—Doxorubicin—ovarian cancer	0.00179	0.00179	CcSEcCtD
Apraclonidine—Feeling abnormal—Paclitaxel—ovarian cancer	0.00178	0.00178	CcSEcCtD
Apraclonidine—Skin disorder—Docetaxel—ovarian cancer	0.00178	0.00178	CcSEcCtD
Apraclonidine—Bradycardia—Epirubicin—ovarian cancer	0.00177	0.00177	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.00177	0.00177	CcSEcCtD
Apraclonidine—Rhinitis—Epirubicin—ovarian cancer	0.00174	0.00174	CcSEcCtD
Apraclonidine—Conjunctivitis—Doxorubicin—ovarian cancer	0.00174	0.00174	CcSEcCtD
Apraclonidine—Haemorrhage—Epirubicin—ovarian cancer	0.00174	0.00174	CcSEcCtD
Apraclonidine—Pharyngitis—Epirubicin—ovarian cancer	0.00172	0.00172	CcSEcCtD
Apraclonidine—Oedema peripheral—Epirubicin—ovarian cancer	0.00171	0.00171	CcSEcCtD
Apraclonidine—Abdominal pain—Paclitaxel—ovarian cancer	0.00171	0.00171	CcSEcCtD
Apraclonidine—Visual impairment—Epirubicin—ovarian cancer	0.00167	0.00167	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.00167	0.00167	CcSEcCtD
Apraclonidine—Insomnia—Docetaxel—ovarian cancer	0.00166	0.00166	CcSEcCtD
Apraclonidine—Paraesthesia—Docetaxel—ovarian cancer	0.00164	0.00164	CcSEcCtD
Apraclonidine—Bradycardia—Doxorubicin—ovarian cancer	0.00164	0.00164	CcSEcCtD
Apraclonidine—Dyspnoea—Docetaxel—ovarian cancer	0.00163	0.00163	CcSEcCtD
Apraclonidine—Somnolence—Docetaxel—ovarian cancer	0.00163	0.00163	CcSEcCtD
Apraclonidine—Eye disorder—Epirubicin—ovarian cancer	0.00162	0.00162	CcSEcCtD
Apraclonidine—Rhinitis—Doxorubicin—ovarian cancer	0.00161	0.00161	CcSEcCtD
Apraclonidine—Haemorrhage—Doxorubicin—ovarian cancer	0.00161	0.00161	CcSEcCtD
Apraclonidine—Pharyngitis—Doxorubicin—ovarian cancer	0.0016	0.0016	CcSEcCtD
Apraclonidine—Hypersensitivity—Paclitaxel—ovarian cancer	0.00159	0.00159	CcSEcCtD
Apraclonidine—Oedema peripheral—Doxorubicin—ovarian cancer	0.00158	0.00158	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.00158	0.00158	CcSEcCtD
Apraclonidine—Fatigue—Docetaxel—ovarian cancer	0.00158	0.00158	CcSEcCtD
Apraclonidine—Angiopathy—Epirubicin—ovarian cancer	0.00158	0.00158	CcSEcCtD
Apraclonidine—Mediastinal disorder—Epirubicin—ovarian cancer	0.00157	0.00157	CcSEcCtD
Apraclonidine—Constipation—Docetaxel—ovarian cancer	0.00156	0.00156	CcSEcCtD
Apraclonidine—Pain—Docetaxel—ovarian cancer	0.00156	0.00156	CcSEcCtD
Apraclonidine—Arrhythmia—Epirubicin—ovarian cancer	0.00155	0.00155	CcSEcCtD
Apraclonidine—Visual impairment—Doxorubicin—ovarian cancer	0.00155	0.00155	CcSEcCtD
Apraclonidine—Asthenia—Paclitaxel—ovarian cancer	0.00155	0.00155	CcSEcCtD
Apraclonidine—Pruritus—Paclitaxel—ovarian cancer	0.00153	0.00153	CcSEcCtD
Apraclonidine—Mental disorder—Epirubicin—ovarian cancer	0.00152	0.00152	CcSEcCtD
Apraclonidine—Erythema—Epirubicin—ovarian cancer	0.00151	0.00151	CcSEcCtD
Apraclonidine—Feeling abnormal—Docetaxel—ovarian cancer	0.00151	0.00151	CcSEcCtD
Apraclonidine—Eye disorder—Doxorubicin—ovarian cancer	0.0015	0.0015	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Docetaxel—ovarian cancer	0.0015	0.0015	CcSEcCtD
Apraclonidine—Tension—Epirubicin—ovarian cancer	0.00148	0.00148	CcSEcCtD
Apraclonidine—Dysgeusia—Epirubicin—ovarian cancer	0.00148	0.00148	CcSEcCtD
Apraclonidine—Diarrhoea—Paclitaxel—ovarian cancer	0.00148	0.00148	CcSEcCtD
Apraclonidine—Nervousness—Epirubicin—ovarian cancer	0.00147	0.00147	CcSEcCtD
Apraclonidine—Angiopathy—Doxorubicin—ovarian cancer	0.00146	0.00146	CcSEcCtD
Apraclonidine—Mediastinal disorder—Doxorubicin—ovarian cancer	0.00145	0.00145	CcSEcCtD
Apraclonidine—Abdominal pain—Docetaxel—ovarian cancer	0.00145	0.00145	CcSEcCtD
Apraclonidine—Arrhythmia—Doxorubicin—ovarian cancer	0.00144	0.00144	CcSEcCtD
Apraclonidine—Dizziness—Paclitaxel—ovarian cancer	0.00143	0.00143	CcSEcCtD
Apraclonidine—Vision blurred—Epirubicin—ovarian cancer	0.00143	0.00143	CcSEcCtD
Apraclonidine—Mental disorder—Doxorubicin—ovarian cancer	0.00141	0.00141	CcSEcCtD
Apraclonidine—Ill-defined disorder—Epirubicin—ovarian cancer	0.0014	0.0014	CcSEcCtD
Apraclonidine—Erythema—Doxorubicin—ovarian cancer	0.0014	0.0014	CcSEcCtD
Apraclonidine—Tension—Doxorubicin—ovarian cancer	0.00137	0.00137	CcSEcCtD
Apraclonidine—Vomiting—Paclitaxel—ovarian cancer	0.00137	0.00137	CcSEcCtD
Apraclonidine—Dysgeusia—Doxorubicin—ovarian cancer	0.00137	0.00137	CcSEcCtD
Apraclonidine—Malaise—Epirubicin—ovarian cancer	0.00136	0.00136	CcSEcCtD
Apraclonidine—Dermatitis—Paclitaxel—ovarian cancer	0.00136	0.00136	CcSEcCtD
Apraclonidine—Nervousness—Doxorubicin—ovarian cancer	0.00136	0.00136	CcSEcCtD
Apraclonidine—Syncope—Epirubicin—ovarian cancer	0.00136	0.00136	CcSEcCtD
Apraclonidine—Headache—Paclitaxel—ovarian cancer	0.00135	0.00135	CcSEcCtD
Apraclonidine—Hypersensitivity—Docetaxel—ovarian cancer	0.00135	0.00135	CcSEcCtD
Apraclonidine—Palpitations—Epirubicin—ovarian cancer	0.00134	0.00134	CcSEcCtD
Apraclonidine—Vision blurred—Doxorubicin—ovarian cancer	0.00132	0.00132	CcSEcCtD
Apraclonidine—Asthenia—Docetaxel—ovarian cancer	0.00131	0.00131	CcSEcCtD
Apraclonidine—Ill-defined disorder—Doxorubicin—ovarian cancer	0.0013	0.0013	CcSEcCtD
Apraclonidine—Pruritus—Docetaxel—ovarian cancer	0.00129	0.00129	CcSEcCtD
Apraclonidine—Myalgia—Epirubicin—ovarian cancer	0.00129	0.00129	CcSEcCtD
Apraclonidine—Chest pain—Epirubicin—ovarian cancer	0.00129	0.00129	CcSEcCtD
Apraclonidine—Nausea—Paclitaxel—ovarian cancer	0.00128	0.00128	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.00128	0.00128	CcSEcCtD
Apraclonidine—Discomfort—Epirubicin—ovarian cancer	0.00127	0.00127	CcSEcCtD
Apraclonidine—Malaise—Doxorubicin—ovarian cancer	0.00126	0.00126	CcSEcCtD
Apraclonidine—Dry mouth—Epirubicin—ovarian cancer	0.00126	0.00126	CcSEcCtD
Apraclonidine—Syncope—Doxorubicin—ovarian cancer	0.00125	0.00125	CcSEcCtD
Apraclonidine—Diarrhoea—Docetaxel—ovarian cancer	0.00125	0.00125	CcSEcCtD
Apraclonidine—Palpitations—Doxorubicin—ovarian cancer	0.00124	0.00124	CcSEcCtD
Apraclonidine—Oedema—Epirubicin—ovarian cancer	0.00123	0.00123	CcSEcCtD
Apraclonidine—Infection—Epirubicin—ovarian cancer	0.00123	0.00123	CcSEcCtD
Apraclonidine—Nervous system disorder—Epirubicin—ovarian cancer	0.00121	0.00121	CcSEcCtD
Apraclonidine—Dizziness—Docetaxel—ovarian cancer	0.00121	0.00121	CcSEcCtD
Apraclonidine—Skin disorder—Epirubicin—ovarian cancer	0.0012	0.0012	CcSEcCtD
Apraclonidine—Chest pain—Doxorubicin—ovarian cancer	0.00119	0.00119	CcSEcCtD
Apraclonidine—Myalgia—Doxorubicin—ovarian cancer	0.00119	0.00119	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.00118	0.00118	CcSEcCtD
Apraclonidine—Discomfort—Doxorubicin—ovarian cancer	0.00118	0.00118	CcSEcCtD
Apraclonidine—Dry mouth—Doxorubicin—ovarian cancer	0.00117	0.00117	CcSEcCtD
Apraclonidine—Vomiting—Docetaxel—ovarian cancer	0.00116	0.00116	CcSEcCtD
Apraclonidine—Dermatitis—Docetaxel—ovarian cancer	0.00115	0.00115	CcSEcCtD
Apraclonidine—Headache—Docetaxel—ovarian cancer	0.00115	0.00115	CcSEcCtD
Apraclonidine—Oedema—Doxorubicin—ovarian cancer	0.00114	0.00114	CcSEcCtD
Apraclonidine—Infection—Doxorubicin—ovarian cancer	0.00113	0.00113	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.00112	0.00112	CcSEcCtD
Apraclonidine—Nervous system disorder—Doxorubicin—ovarian cancer	0.00112	0.00112	CcSEcCtD
Apraclonidine—Insomnia—Epirubicin—ovarian cancer	0.00112	0.00112	CcSEcCtD
Apraclonidine—Skin disorder—Doxorubicin—ovarian cancer	0.00111	0.00111	CcSEcCtD
Apraclonidine—Paraesthesia—Epirubicin—ovarian cancer	0.00111	0.00111	CcSEcCtD
Apraclonidine—Dyspnoea—Epirubicin—ovarian cancer	0.0011	0.0011	CcSEcCtD
Apraclonidine—Somnolence—Epirubicin—ovarian cancer	0.0011	0.0011	CcSEcCtD
Apraclonidine—Nausea—Docetaxel—ovarian cancer	0.00109	0.00109	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.00107	0.00107	CcSEcCtD
Apraclonidine—Fatigue—Epirubicin—ovarian cancer	0.00106	0.00106	CcSEcCtD
Apraclonidine—Pain—Epirubicin—ovarian cancer	0.00106	0.00106	CcSEcCtD
Apraclonidine—Constipation—Epirubicin—ovarian cancer	0.00106	0.00106	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.00104	0.00104	CcSEcCtD
Apraclonidine—Insomnia—Doxorubicin—ovarian cancer	0.00103	0.00103	CcSEcCtD
Apraclonidine—Paraesthesia—Doxorubicin—ovarian cancer	0.00103	0.00103	CcSEcCtD
Apraclonidine—Dyspnoea—Doxorubicin—ovarian cancer	0.00102	0.00102	CcSEcCtD
Apraclonidine—Feeling abnormal—Epirubicin—ovarian cancer	0.00102	0.00102	CcSEcCtD
Apraclonidine—Somnolence—Doxorubicin—ovarian cancer	0.00102	0.00102	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Epirubicin—ovarian cancer	0.00101	0.00101	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000986	0.000986	CcSEcCtD
Apraclonidine—Fatigue—Doxorubicin—ovarian cancer	0.000985	0.000985	CcSEcCtD
Apraclonidine—Constipation—Doxorubicin—ovarian cancer	0.000977	0.000977	CcSEcCtD
Apraclonidine—Pain—Doxorubicin—ovarian cancer	0.000977	0.000977	CcSEcCtD
Apraclonidine—Abdominal pain—Epirubicin—ovarian cancer	0.000976	0.000976	CcSEcCtD
Apraclonidine—Feeling abnormal—Doxorubicin—ovarian cancer	0.000941	0.000941	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000934	0.000934	CcSEcCtD
Apraclonidine—Hypersensitivity—Epirubicin—ovarian cancer	0.000909	0.000909	CcSEcCtD
Apraclonidine—Abdominal pain—Doxorubicin—ovarian cancer	0.000903	0.000903	CcSEcCtD
Apraclonidine—Asthenia—Epirubicin—ovarian cancer	0.000886	0.000886	CcSEcCtD
Apraclonidine—Pruritus—Epirubicin—ovarian cancer	0.000873	0.000873	CcSEcCtD
Apraclonidine—Diarrhoea—Epirubicin—ovarian cancer	0.000844	0.000844	CcSEcCtD
Apraclonidine—Hypersensitivity—Doxorubicin—ovarian cancer	0.000841	0.000841	CcSEcCtD
Apraclonidine—Asthenia—Doxorubicin—ovarian cancer	0.000819	0.000819	CcSEcCtD
Apraclonidine—Dizziness—Epirubicin—ovarian cancer	0.000816	0.000816	CcSEcCtD
Apraclonidine—Pruritus—Doxorubicin—ovarian cancer	0.000808	0.000808	CcSEcCtD
Apraclonidine—Vomiting—Epirubicin—ovarian cancer	0.000785	0.000785	CcSEcCtD
Apraclonidine—Diarrhoea—Doxorubicin—ovarian cancer	0.000781	0.000781	CcSEcCtD
Apraclonidine—Dermatitis—Epirubicin—ovarian cancer	0.000777	0.000777	CcSEcCtD
Apraclonidine—Headache—Epirubicin—ovarian cancer	0.000773	0.000773	CcSEcCtD
Apraclonidine—Dizziness—Doxorubicin—ovarian cancer	0.000755	0.000755	CcSEcCtD
Apraclonidine—Nausea—Epirubicin—ovarian cancer	0.000733	0.000733	CcSEcCtD
Apraclonidine—Vomiting—Doxorubicin—ovarian cancer	0.000726	0.000726	CcSEcCtD
Apraclonidine—Dermatitis—Doxorubicin—ovarian cancer	0.000719	0.000719	CcSEcCtD
Apraclonidine—Headache—Doxorubicin—ovarian cancer	0.000715	0.000715	CcSEcCtD
Apraclonidine—Nausea—Doxorubicin—ovarian cancer	0.000678	0.000678	CcSEcCtD
